Article
Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.
PloS one - 1 Jan 2014
Mukonzo Jackson K, Owen Joel S, Ogwal-Okeng Jasper, Kuteesa Ronald B, Nanzigu Sarah, Sewankambo Nelson, Thabane Lehana, Gustafsson Lars L, Ross Colin, Aklillu Eleni
Abstract excerpt
BACKGROUND: Pharmacogenetics contributes to inter-individual variability in pharmacokinetics (PK) of efavirenz (EFV), leading to variations in both efficacy and toxicity. The purpose of this study was to assess the effect of genetic factors on EFV pharmacokinetics, treatment outcomes and genotype based EFV dose recommendations for adult HIV-1 infected Ugandans. METHODS: In total, 556 steady-state plasma EFV...
Topics
Join the communities discussing this publication.